Cathy Kelly
Senior Writer
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
Point-of-Sale Rebates Gaining Traction In Employer-Sponsored Insurance
Survey by National Business Group on Health also finds growing momentum behind use of copay accumulator programs.
CVS Will Retain $300M In Drug Rebates In 2018, PBM Says
CEO Merlo downplays importance of rebates to the firm’s financials as he rebuts accusations that PBMs cause high list prices for drugs.
CVS Launching Program To Exclude New Drugs Deemed Not Cost Effective
Highest-Cost Drugs Could Feel Biggest Pinch From Part B Step Therapy Policy
Biosimilars for Remicade and Neulasta could get boost, and off-label Avastin use for age-related macular degeneration could increase, challenging Eylea and Lucentis.
Step Therapy For Medicare Part B Drugs Will Lower Costs By 20%, HHS Projects
Beginning in 2019, Medicare Advantage plans may use step therapy in Part B, potentially including “cross management” with Part D drugs, under new guidance from the Centers for Medicare and Medicaid Services.
Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.